Northern Trust Corp lifted its position in Antares Pharma, Inc. (NASDAQ:ATRS) by 478.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,654,266 shares of the specialty pharmaceutical company’s stock after buying an additional 1,368,131 shares during the quarter. Northern Trust Corp owned about 1.06% of Antares Pharma worth $5,327,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new stake in shares of Antares Pharma in the 2nd quarter valued at approximately $651,000. Menta Capital LLC bought a new stake in Antares Pharma during the second quarter worth approximately $297,000. New York State Common Retirement Fund bought a new stake in Antares Pharma during the second quarter worth approximately $391,000. Nationwide Fund Advisors bought a new stake in Antares Pharma during the second quarter worth approximately $260,000. Finally, TIAA CREF Investment Management LLC bought a new stake in Antares Pharma during the second quarter worth approximately $1,251,000. 36.84% of the stock is owned by institutional investors and hedge funds.
ATRS has been the subject of a number of recent analyst reports. Vetr raised Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research report on Monday, July 24th. Piper Jaffray Companies set a $4.00 target price on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. HC Wainwright set a $5.00 target price on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, ValuEngine cut Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $3.84.
ILLEGAL ACTIVITY WARNING: “Northern Trust Corp Purchases 1,368,131 Shares of Antares Pharma, Inc. (ATRS)” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://transcriptdaily.com/2017/11/17/northern-trust-corp-purchases-1368131-shares-of-antares-pharma-inc-atrs.html.
Shares of Antares Pharma, Inc. (NASDAQ ATRS) opened at $1.89 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. Antares Pharma, Inc. has a 12-month low of $1.58 and a 12-month high of $4.09.
Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.01 million. The business’s revenue was up 11.9% compared to the same quarter last year. equities analysts predict that Antares Pharma, Inc. will post -0.11 earnings per share for the current fiscal year.
In other news, Director Thomas J. Garrity sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total value of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by insiders.
Antares Pharma Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.